ストックスクリーナーアプリを入手
3.34
0.00%
0.00
アフターアワーズ：
3.36
0.02
+0.60%
4 D Molecular Therapeutics Inc (FDMT) 最新ニュース
X-linked retinitis pigmentosa Pipeline Analysis and Clinical - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Geode Capital Management LLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (E+) Rating at Weiss Ratings - Defense World
4D Molecular Therapeutics Inc [FDMT] Shares Rise 0.59 % on Wednesday - knoxdaily.com
Retinitis Pigmentosa Drugs Market 2034: EMA, PDMA, FDA Approvals Clinical Trials, Prevalence, Medication, Revenue, Statistics, Pipeline and Companies by DelveInsight - The Globe and Mail
American Express Just Delivered Fantastic News for Investors. Here's Why the Warren Buffett Stock Is a Buy Now. - The Globe and Mail
Orion Mine Finance selling at Allied Gold (AAUC) - The Globe and Mail
How should investors view 4D Molecular Therapeutics Inc (FDMT)? - uspostnews.com
Discover Fractyl Health And 2 More Promising Penny Stocks - simplywall.st
Analyzing 4D Molecular Therapeutics (NASDAQ:FDMT) & Gilead Sciences (NASDAQ:GILD) - Defense World
JPMorgan Chase & Co. Raises Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
What is Leerink Partnrs’ Estimate for FDMT FY2026 Earnings? - Defense World
Vanguard Group Inc. Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com
American Century Companies Inc. Acquires 4,429 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Wellington Management Group LLP Purchases 11,089 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
8,600 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Acquired by KLP Kapitalforvaltning AS - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of “Moderate Buy” by Analysts - Defense World
4DMT Announces New Employment Inducement Grants - GlobeNewswire
4D Molecular Therapeutics, Inc. (FDMT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - ACCESS Newswire
Weiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Raymond James Financial Inc. Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics stock hits 52-week low at $3.46 - Investing.com India
4D Molecular Therapeutics stock hits 52-week low at $3.46 By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Sells 29,708 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
PNC Financial Services Group Inc. Raises Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire
Here Is How Powerful 4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is - Stocks Register
Connor Clark & Lunn Investment Management Ltd. Raises Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Weiss Ratings Reiterates Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - The AM Reporter
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 15.1% in February - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.63 Average PT from Analysts - The AM Reporter
Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $30.63 - Defense World
M&T Bank Corp Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdles - Investing.com
Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00 by Analysts at Bank of America - Defense World
4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy -March 10, 2025 at 09:31 am EDT - Marketscreener.com
4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial - TipRanks
4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration - Nasdaq
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewswire
4D Molecular Launches Pivotal Phase 3 Trial for Revolutionary Eye Treatment - StockTitan
Rhumbline Advisers Acquires 3,675 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by New York State Common Retirement Fund - Defense World
FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald - Defense World
0.19%
大文字化:
|
ボリューム (24 時間):